ArticleQuantitative imaging in medicine and surgery2026
AI-assisted compressed sensing and gadoxetic acid-enhanced MRI for evaluating colorectal liver metastases in complex hepatic backgrounds: a prospective 5T MRI study.
Article in Quantitative imaging in medicine and surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- 5.0 T versus 1.5 T and 3.0 T upper abdominal MRI: a prospective two‑cohort study of image quality and diagnostic confidence.European radiology · 2026Article
- Deep learning-based high-resolution united compressed sensing for gadoxetic acid-enhanced liver magnetic resonance imaging in the detection of colorectal liver metastases.Quantitative imaging in medicine and surgery · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The detection of colorectal liver metastases (CRLMs) in complex hepatic backgrounds due to chemotherapy-associated liver injury (CALI) and prior local CRLM treatment is challenging and requires advanced imaging modalities capable of providing both precise lesion detection and CALI assessments. This study aimed to evaluate the diagnostic performance of 5 Tesla (T) multimodal magnetic resonance imaging (MRI) for detecting CRLMs while accurately assessing the hepatic background. Methods: A total of 35 post-chemotherapy patients with suspected CRLMs and a combined total of 118 MRI-identified lesions were prospectively enrolled. Participants underwent 5T liver multimodal MRI with acquisition of: T1-weighted (T1W) in/out-of-phase imaging and proton density fat fraction (PDFF), susceptibility-weighted imaging with fast technique (uSWIFT), and standard hepatic gadoxetic acid-enhanced MRI (EOB-MRI) with three-dimensional (3D) isotropic T1W fast spoiled gradient-recalled echo (FSPGR) hepatobiliary phase imaging and artificial intelligence (AI)-assisted compressed sensing (ACS-HBP) (acquisition voxel size 1.2 mm Results: The combination of ACS-HBP and diffusion-weighted imaging (DWI) demonstrated excellent diagnostic performance in detecting CRLMs, yielding the highest sensitivity (97.2%) and PPV (94.6-95.5%), whereas for small lesions (≤10 mm), the combination yielded a sensitivity of 95.7%, outperforming DWI alone (66.0%). Neither CALI nor a prior history of local CRLM treatment had a significant impact on diagnostic performance (all P>0.05). On ACS-HBP imaging, 86.1% (93/108) of all lesions and 71.7% (33/46) of lesions ≤10 mm presented with a target sign (central hyperintensity with a hypointense rim), or reverse target sign (central hypointensity with a hyperintense rim). Conclusions: The combination of ACS and 5T EOB-MRI demonstrates excellent diagnostic performance for CRLMs, including for ≤10 mm lesions, with high sensitivity and PPV across diverse hepatic backgrounds. On HBP imaging, CRLMs characteristically display target and reverse-target signs, especially in lesions ≤10 mm, facilitating differentiation from hepatic cysts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.